Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 13/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 12/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 12/20 | 0.40 |
| ▸ | DHODH | Q02127 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15608736 | 0.85 | PIM1 (0.42) | PIM1PIM3PIM2KDM4ETDP1 | |
| SCHEMBL12077220 | 0.83 | PIM1 (0.42) | PIM1PIM3PIM2KDM4EL3MBTL1 | |
| SCHEMBL29359828 | 0.83 | PIM2 (0.41) | PIM1PIM3PIM2DHODHKDM4E | |
| SCHEMBL318527 | 0.83 | PIM1 (0.44) | PIM1PIM3PIM2KDM4EL3MBTL1 | |
| SCHEMBL12078277 | 0.83 | PIM2 (0.41) | PIM1PIM3PIM2DHODHKDM4E | |
| SCHEMBL12697097 | 0.83 | RXRA (0.36) | PIM1PIM3PIM2KDM4EL3MBTL1 | |
| SCHEMBL319232 | 0.83 | PIM1 (0.44) | PIM1PIM3PIM2KDM4EMAPT | |
| SCHEMBL319157 | 0.82 | PIM1 (0.44) | PIM1PIM3PIM2KDM4EL3MBTL1 | |
| SCHEMBL15609247 | 0.82 | PIM1 (0.44) | PIM1PIM3PIM2KDM4EL3MBTL1 | |
| SCHEMBL318934 | 0.82 | PIM2 (0.41) | PIM1PIM3PIM2KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112794860-B | Oxazole pyrimidone amide compound or medicinal salt thereof, preparation method and application | 上海肇钰医药科技有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-112794860-A | Oxazole pyrimidone amide compound or medicinal salt thereof, preparation method and application | 上海肇钰医药科技有限公司 | 2021-05-14 | — | — | CN | disclosed |
| EP-2861585-B1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-01-09 | — | — | EP | disclosed |
| EP-2861585-B1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-01-09 | — | — | EP | disclosed |
| US-9173883-B2 | Ring-substituted N-pyridinyl amides as kinase inhibitors | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173883-B2 | Ring-substituted N-pyridinyl amides as kinase inhibitors | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173883-B2 | Ring-substituted N-pyridinyl amides as kinase inhibitors | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| WO-2012120428-A1 | NOVEL KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012120428-A1 | NOVEL KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | PIM1, PIM2, MAP3K1 | PIM1 1/4885PIM3 4/4885PIM2 2/4885 |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.